Stacy Chronister, DO
Internal Medicine · Tulsa, OKNPI 1194987750
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,203 of the $162,670 with a category attached, or 78.2%. Novo Nordisk accounts for 98.3% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $46,653, more than ten times the $1,026 reported in 2019. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $528.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$160K
- Viiv Healthcare Company$821
- Gilead$591
- AstraZeneca$290
- Johnson & Johnson$240
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$126
- plus $718 from 17 others
What the payments were for
- Consulting fees$22,61014%
- Speaking & faculty fees$127,20378%
- Travel & lodging$6,4294%
- Food & beverage$6,3954%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 160 | $159,883 |
| Viiv Healthcare Company | 49 | $821 |
| Gilead | 35 | $591 |
| AstraZeneca | 7 | $290 |
| Johnson & Johnson(2 entities) | 15 | $240 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $126 |
| AbbVie(2 entities) | 6 | $120 |
| EMD Serono, Inc. | 3 | $81 |
| Novartis | 5 | $67 |
| Boehringer Ingelheim | 4 | $62 |
| Amgen | 3 | $50 |
| Theratechnologies Inc. | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Vyera Pharmaceuticals, LLC | 2 | $38 |
| Merck | 3 | $35 |
| Janssen Products, LP | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
| Abbott | 1 | $23 |
| Pfizer | 1 | $22 |
| Sanofi | 1 | $20 |
| Exact Sciences | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$97,953
- Saxenda$37,159
- BREZTRI AEROSPHERE$121
- BREZTRI$110
How this compares
$162,670 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $16,747 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $447 |
| Gabapentin | 17 | $287 |
| Atorvastatin Calcium | 33 | $203 |
| Omeprazole | 11 | $170 |
| Lisinopril | 21 | $129 |
| Levothyroxine Sodium | 11 | $84 |
| Tamsulosin Hcl | 14 | $81 |
| Amlodipine Besylate | 16 | $75 |
| Carvedilol | 17 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $62 | $16,74717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$173K
- Layth Al AttarTulsa$35K
- Gerard McNultyTulsa$27K
- Peter LantzTulsa$23K
- Sudip TripathyTulsa$21K
- John RuffingTulsa$21K
- Joseph ReeseTulsa$18K
- Mark GallesTulsa$17K
- Diana ChenTulsa$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.